Lélia Delamarre

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 10

Top Venues

Cancer immunology research

Oncoimmunology

Nature reviews. Cancer

Molecular & cellular oncology

Genentech Inc

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Genentech Inc

United States

Senior Scientist :: Cancer Immunology

Publications

Junghyun Lim, Ryan Rodriguez, Katherine Williams, John Silva, Alan G Gutierrez, Paul Tyler, Faezzah Baharom, Tao Sun, Eva Lin, Scott E Martin, Brandon D Kayser, Robert J Johnston, Ira Mellman, Lélia Delamarre, Nathaniel R West, Sören Müller, Yan Qu, Klaus Heger
The Exonuclease TREX1 Constitutes an Innate Immune Checkpoint Limiting cGAS/STING-Mediated Antitumor Immunity. Cancer immunology research 12 (6) (2024)
Junghyun Lim, Ryan Rodriguez, Katherine Williams, John Silva, Alan G Gutierrez, Paul Tyler, Faezzah Baharom, Tao Sun, Eva Lin, Scott E Martin, Brandon D Kayser, Robert J Johnston, Ira Mellman, Lélia Delamarre, Nathaniel R West, Sören Müller, Yan Qu, Klaus Heger
The exonuclease TREX1 constitutes an innate immune checkpoint limiting cGAS/STING-mediated antitumor immunity. Cancer immunology research (2024)
Junghyun Lim, Ryan Rodriguez, Katherine Williams, John Silva, Alan G Gutierrez, Paul Tyler, Faezzah Baharom, Tao Sun, Eva Lin, Scott E Martin, Brandon D Kayser, Robert J Johnston, Ira Mellman, Lélia Delamarre, Nathaniel R West, Sören Müller, Yan Qu, Klaus Heger
The Exonuclease TREX1 Constitutes an Innate Immune Checkpoint Limiting cGAS/STING-Mediated Antitumor Immunity. Cancer immunology research 12 (6) (2024)
Junghyun Lim, Ryan Rodriguez, Katherine Williams, John Silva, Alan G Gutierrez, Paul Tyler, Faezzah Baharom, Tao Sun, Eva Lin, Scott E Martin, Brandon D Kayser, Robert J Johnston, Ira Mellman, Lélia Delamarre, Nathaniel R West, Sören Müller, Yan Qu, Klaus Heger
The Exonuclease TREX1 Constitutes an Innate Immune Checkpoint Limiting cGAS/STING-Mediated Antitumor Immunity. Cancer immunology research 12 (6) (2024)
Ann-Jay Tong, Rebecca Leylek, Anna-Maria Herzner, Diamanda Rigas, Sara Wichner, Craig Blanchette, Siri Tahtinen, Christopher C Kemball, Ira Mellman, Benjamin Haley, Emily C Freund, Lélia Delamarre
Nucleotide modifications enable rational design of TLR7-selective ligands by blocking RNase cleavage. The Journal of experimental medicine 221 (2) (2023)
Aude-Hélène Capietto, Reyhane Hoshyar, Lélia Delamarre
Sources of Cancer Neoantigens beyond Single-Nucleotide Variants. International journal of molecular sciences 23 (17) (2022)
Suchit Jhunjhunwala, Christian Hammer, Lélia Delamarre
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Nature reviews. Cancer 21 (5) (2021)
Aude-Hélène Capietto, Suchit Jhunjhunwala, Lélia Delamarre
Cancer neoantigens and immunogenicity: mutation position matters. Molecular & cellular oncology 7 (3) (2020)
Emel Esen, Ismail Sergin, Rajiv Jesudason, Patricia Himmels, Joshua D Webster, Hua Zhang, Min Xu, Robert Piskol, Erin McNamara, Stephen Gould, Aude-Hélène Capietto, Lélia Delamarre, Kevin B Walsh, Weilan Ye
MAP4K4 negatively regulates CD8 T cell-mediated antitumor and antiviral immunity. Science immunology 5 (45) (2020)
Mathias Vormehr, Sophie Lehar, Lena M Kranz, Siri Tahtinen, Yoko Oei, Vincent Javinal, Lélia Delamarre, Kerstin C Walzer, Mustafa Diken, Sebastian Kreiter, Ira Mellman, Ugur Sahin, Jill M Schartner, Özlem Türeci
Dexamethasone premedication suppresses vaccine-induced immune responses against cancer. Oncoimmunology 9 (1) (2020)

Lélia Delamarre.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Lélia Delamarre